Rhythm Pharmaceuticals
RYTM
90 hedge funds and large institutions have $191M invested in Rhythm Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 36 closing their positions.
1,294% more call options, than puts
Call options by funds: $1.67M | Put options by funds: $120K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.88% less ownership
Funds ownership: 97.07% → 91.19% (-5.9%)
19% less funds holding
Funds holding: 111 → 90 (-21)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
50% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 36
66% less capital invested
Capital invested by funds: $563M → $191M (-$372M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$8.21M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.07M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.98M |
| 4 |
E
Ergoteles
New York
|
+$1.16M |
| 5 |
Morgan Stanley
New York
|
+$959K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$11.5M |
| 2 |
Janus Henderson Group
London,
|
-$4.77M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.66M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.07M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.62M |
RYTM Hedge Fund Activity: Q2 2022 in Review
90 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2022, worth a combined $191M — down 66% from $563M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of RYTM and 18 opened new positions — a net loss of 18 holders — while 31 trimmed existing stakes and 23 added.
The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $8.21M. The largest seller was BlackRock, cutting an estimated $11.5M.
- 90 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2022, down from 111 in Q1 2022.
- Funds reported $191M of Rhythm Pharmaceuticals stock for Q2 2022, down 66% quarter-over-quarter.
- 18 funds opened new Rhythm Pharmaceuticals positions in Q2 2022 and 36 closed out, a net change of -18 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2022 was Alkeon Capital Management, an estimated $8.21M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2022 was BlackRock, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2022.